Labels for the exact product
A label is a useful place to check approved uses, restrictions and warnings. It describes a particular product; the ingredient name alone doesn't make every preparation the same.
- Wegovy (semaglutide) prescribing information: the source for the weight-management use and safety questions discussed here.
- Ozempic (semaglutide) injection prescribing information: the source for its adult type 2 diabetes use and product-specific instructions.
Studies behind the main findings
These papers answer different questions. The research guide shows why the comparison and the people studied stay close to a result.
- STEP 1, on weight loss: Wilding and colleagues, New England Journal of Medicine, 2021. Adults without diabetes received semaglutide or placebo, with lifestyle support. This is the weight-change comparison on the effects page.
- SELECT, on cardiovascular events: Lincoff and colleagues, New England Journal of Medicine, 2023. This trial involved adults with existing cardiovascular disease and overweight or obesity, without diabetes. It's the example behind the research page's discussion of risk.
- The STEP 1 follow-up after stopping: Wilding and colleagues, Diabetes, Obesity and Metabolism, 2022. The extension analysed 327 participants from the original trial. Treatment and lifestyle support both stopped. Average regain in the semaglutide group informs questions about longer-term care; it isn't a prediction for every person who stops.
- Digestive side effects across weight-management trials: Wharton and colleagues, Diabetes, Obesity and Metabolism, 2022. This combined analysis describes when these problems tended to appear and how severe they were.
- Semaglutide safety reports after marketing: Journal of Diabetes Investigation, 2024. Reports help flag concerns for investigation; they don't establish how often a problem happens among everyone taking the medicine.
FDA explanations about compounding
- Compounding questions and answers: why compounded medicines are not FDA-approved, and what that distinction means.
- Concerns about unapproved GLP-1 medicines: the source for the dosing-error reports discussed here.
- Compounding-policy updates: the FDA's dated explanations, including the April 2026 account of limits on copies.
The trial papers describe manufactured medicines. They don't show that a compounded preparation brings the same benefits.
These links are here for checking a claim or reading further. None can assess your circumstances in the way an individual prescription review can.